The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The FDA granted Welireg a priority review after it showed promising outcomes for patients with pretreated advanced renal cell carcinoma. The Food and Drug Administration (FDA) granted a priority ...

Two months ago, when Merck revealed its phase 3 trial in renal cell carcinoma achieved its primary endpoint, as Welireg (belzutifan) racked up a decisive win over Novartis’ chemotherapy Afinitor in ...

Merck’s first quarter results were shaped by robust momentum in its oncology and animal health divisions, as well as ...

Since Merck secured approval for kidney cancer pill and blockbuster hopeful Welireg (belzutifan) in August of 2021, sales have grown slowly but surely. With a second FDA nod on Thursday for a much ...

Belzutifan–lenvatinib delivered a clinically meaningful PFS advantage over cabozantinib after prior ICI exposure, with consistent benefit across interim analyses in a 747-patient randomized trial.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

JACKSONVILLE, Fla. — "I just want there to be some hope... life with VHL is different from what most other people deal with... I've had to deal with it two ways one as a patient and one as a parent ...

Findings from the LITESPARK-005 trial showed a statistically significant improvement in progression free survival with belzutifan compared with everolimus. The Food and Drug Administration (FDA) has ...

Merck & Co Inc (NYSE:MRK) released topline results from LITESPARK-005, a Phase 3 trial investigating WELIREG (belzutifan), Merck's oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor.

This is the first positive Phase 3 trial of a HIF-2 alpha inhibitor in combination with a multi-targeted tyrosine kinase inhibitor, the first for patients with RCC whose disease progressed on or after ...